A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.

Inclusion Criteria:

Histological or cytological diagnosis of a relevant tumor type as per the study protocol and not candidates for curative surgery or radiation therapy
Available tumor tissue (archival or newly obtained core or excisional biopsy)
Adequate hematologic and end organ function as measured by laboratory screening panel in the 14 days prior to treatment
Life expectancy greater than 12 weeks.
ECOG performance status of 0 to 1
Adequate contraception for women of childbearing potential
Pre-specified wash-out of prior anti-PD1/PDL-1 therapy

Exclusion Criteria:

Concurrent active malignancy
Major surgery within 4 weeks of treatment
Subjects with active, known or suspected autoimmune diseases
Prior treatment with CD137 agonists, anti-CTLA-4 and anti-TIGIT antibodies
History of any Grade 3 or 4 immune-related AE toxicity from prior immunotherapy that resulted in treatment discontinuation
History of immune-related adverse events that lead to discontinuation of anti-PD-1 or PDL-1 therapy
Active infections of HIV, hepatitis B, hepatitis C
Medical illness or abnormal laboratory finding that would, in the Study Investigator's judgement, increase the risk to the subject associated with participation in the study
Pregnancy in female subjects